Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 198


Intratumor Heterogeneity of the Estrogen Receptor and the Long-term Risk of Fatal Breast Cancer.

Lindström LS, Yau C, Czene K, Thompson CK, Hoadley KA, Van't Veer LJ, Balassanian R, Bishop JW, Carpenter PM, Chen YY, Datnow B, Hasteh F, Krings G, Lin F, Zhang Y, Nordenskjöld B, Stål O, Benz CC, Fornander T, Borowsky AD, Esserman LJ; STO Trialists Group.

J Natl Cancer Inst. 2018 Jan 19. doi: 10.1093/jnci/djx270. [Epub ahead of print]


Raptor localization predicts prognosis and tamoxifen response in estrogen receptor-positive breast cancer.

Bostner J, Alayev A, Berman AY, Fornander T, Nordenskjöld B, Holz MK, Stål O.

Breast Cancer Res Treat. 2018 Feb;168(1):17-27. doi: 10.1007/s10549-017-4508-x. Epub 2017 Nov 11.


Tamoxifen therapy benefit for patients with 70-gene signature high and low risk.

van 't Veer LJ, Yau C, Yu NY, Benz CC, Nordenskjöld B, Fornander T, Stål O, Esserman LJ, Lindström LS.

Breast Cancer Res Treat. 2017 Nov;166(2):593-601. doi: 10.1007/s10549-017-4428-9. Epub 2017 Aug 4.


Use of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 Decades.

Esserman LJ, Yau C, Thompson CK, van 't Veer LJ, Borowsky AD, Hoadley KA, Tobin NP, Nordenskjöld B, Fornander T, Stål O, Benz CC, Lindström LS.

JAMA Oncol. 2017 Nov 1;3(11):1503-1510. doi: 10.1001/jamaoncol.2017.1261.


Long-term effects on the incidence of second primary cancers in a randomized trial of two and five years of adjuvant tamoxifen.

Rosell J, Nordenskjöld B, Bengtsson NO, Fornander T, Hatschek T, Lindman H, Malmström PO, Wallgren A, Stål O, Carstensen J.

Acta Oncol. 2017 Apr;56(4):614-617. doi: 10.1080/0284186X.2016.1273547. Epub 2017 Jan 12.


Two Years of Adjuvant Tamoxifen Provides a Survival Benefit Compared With No Systemic Treatment in Premenopausal Patients With Primary Breast Cancer: Long-Term Follow-Up (> 25 years) of the Phase III SBII:2pre Trial.

Ekholm M, Bendahl PO, Fernö M, Nordenskjöld B, Stål O, Rydén L.

J Clin Oncol. 2016 Jul 1;34(19):2232-8. doi: 10.1200/JCO.2015.65.6272. Epub 2016 May 9.


Androgen receptor expression predicts beneficial tamoxifen response in oestrogen receptor-α-negative breast cancer.

Hilborn E, Gacic J, Fornander T, Nordenskjöld B, Stål O, Jansson A.

Br J Cancer. 2016 Feb 2;114(3):248-55. doi: 10.1038/bjc.2015.464. Epub 2016 Jan 7.


ERRα Is a Marker of Tamoxifen Response and Survival in Triple-Negative Breast Cancer.

Manna S, Bostner J, Sun Y, Miller LD, Alayev A, Schwartz NS, Lager E, Fornander T, Nordenskjöld B, Yu JJ, Stål O, Holz MK.

Clin Cancer Res. 2016 Mar 15;22(6):1421-31. doi: 10.1158/1078-0432.CCR-15-0857. Epub 2015 Nov 5.


Loss of protein tyrosine phosphatase, non-receptor type 2 is associated with activation of AKT and tamoxifen resistance in breast cancer.

Karlsson E, Veenstra C, Emin S, Dutta C, Pérez-Tenorio G, Nordenskjöld B, Fornander T, Stål O.

Breast Cancer Res Treat. 2015 Aug;153(1):31-40. doi: 10.1007/s10549-015-3516-y. Epub 2015 Jul 25.


Final 10-year results of the Breast International Group 2-98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer.

Sonnenblick A, Francis PA, Azim HA Jr, de Azambuja E, Nordenskjöld B, Gutiérez J, Quinaux E, Mastropasqua MG, Ameye L, Anderson M, Lluch A, Gnant M, Goldhirsch A, Di Leo A, Barnadas A, Cortes-Funes H, Piccart M, Crown J.

Eur J Cancer. 2015 Aug;51(12):1481-9. doi: 10.1016/j.ejca.2015.03.018. Epub 2015 Jun 11.


S6 kinase signaling: tamoxifen response and prognostic indication in two breast cancer cohorts.

Bostner J, Karlsson E, Eding CB, Perez-Tenorio G, Franzén H, Konstantinell A, Fornander T, Nordenskjöld B, Stål O.

Endocr Relat Cancer. 2015 Jun;22(3):331-43. doi: 10.1530/ERC-14-0513.


No clear effect of postoperative radiotherapy on survival of breast cancer patients with one to three positive nodes: a population-based study.

Nordenskjöld AE, Fohlin H, Albertsson P, Arnesson LG, Chamalidou C, Einbeigi Z, Holmberg E, Nordenskjöld B, Karlsson P; Swedish Western and Southeastern Breast Cancer Groups.

Ann Oncol. 2015 Jun;26(6):1149-54. doi: 10.1093/annonc/mdv159. Epub 2015 Apr 3.


Lack of G protein-coupled estrogen receptor (GPER) in the plasma membrane is associated with excellent long-term prognosis in breast cancer.

Sjöström M, Hartman L, Grabau D, Fornander T, Malmström P, Nordenskjöld B, Sgroi DC, Skoog L, Stål O, Leeb-Lundberg LM, Fernö M.

Breast Cancer Res Treat. 2014 May;145(1):61-71. doi: 10.1007/s10549-014-2936-4. Epub 2014 Apr 9.


C-X-C ligand 10 and C-X-C receptor 3 status can predict tamoxifen treatment response in breast cancer patients.

Hilborn E, Sivik T, Fornander T, Stål O, Nordenskjöld B, Jansson A.

Breast Cancer Res Treat. 2014 May;145(1):73-82. doi: 10.1007/s10549-014-2933-7. Epub 2014 Apr 9.


Oestrogen receptor co-activator AIB1 is a marker of tamoxifen benefit in postmenopausal breast cancer.

Weiner M, Skoog L, Fornander T, Nordenskjöld B, Sgroi DC, Stål O.

Ann Oncol. 2013 Aug;24(8):1994-9. doi: 10.1093/annonc/mdt159. Epub 2013 May 12.


Effects of adjuvant tamoxifen therapy on cardiac disease: results from a randomized trial with long-term follow-up.

Rosell J, Nordenskjöld B, Bengtsson NO, Fornander T, Hatschek T, Lindman H, Malmström PO, Wallgren A, Stål O, Carstensen J.

Breast Cancer Res Treat. 2013 Apr;138(2):467-73. doi: 10.1007/s10549-013-2457-6. Epub 2013 Mar 2.


Wwox expression may predict benefit from adjuvant tamoxifen in randomized breast cancer patients.

Göthlin Eremo A, Wegman P, Stål O, Nordenskjöld B, Fornander T, Wingren S.

Oncol Rep. 2013 Apr;29(4):1467-74. doi: 10.3892/or.2013.2261. Epub 2013 Jan 31.


Akt2 expression is associated with good long-term prognosis in oestrogen receptor positive breast cancer.

Fohlin H, Pérez-Tenorio G, Fornander T, Skoog L, Nordenskjöld B, Carstensen J, Stål O.

Eur J Cancer. 2013 Apr;49(6):1196-204. doi: 10.1016/j.ejca.2012.12.006. Epub 2013 Jan 8.


Overall survival benefit for sequential doxorubicin-docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer--8-year results of the Breast International Group 02-98 phase III trial.

Oakman C, Francis PA, Crown J, Quinaux E, Buyse M, De Azambuja E, Margeli Vila M, Andersson M, Nordenskjöld B, Jakesz R, Thürlimann B, Gutiérrez J, Harvey V, Punzalan L, Dell'orto P, Larsimont D, Steinberg I, Gelber RD, Piccart-Gebhart M, Viale G, Di Leo A.

Ann Oncol. 2013 May;24(5):1203-11. doi: 10.1093/annonc/mds627. Epub 2013 Jan 4.


Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit.

Bostner J, Karlsson E, Pandiyan MJ, Westman H, Skoog L, Fornander T, Nordenskjöld B, Stål O.

Breast Cancer Res Treat. 2013 Jan;137(2):397-406. doi: 10.1007/s10549-012-2376-y. Epub 2012 Dec 15.


17β-Hydroxysteroid dehydrogenase type 14 is a predictive marker for tamoxifen response in oestrogen receptor positive breast cancer.

Sivik T, Gunnarsson C, Fornander T, Nordenskjöld B, Skoog L, Stål O, Jansson A.

PLoS One. 2012;7(7):e40568. doi: 10.1371/journal.pone.0040568. Epub 2012 Jul 6.


Prognostic utility of HOXB13:IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial.

Jerevall PL, Ma XJ, Li H, Salunga R, Kesty NC, Erlander MG, Sgroi DC, Holmlund B, Skoog L, Fornander T, Nordenskjöld B, Stål O.

Br J Cancer. 2011 May 24;104(11):1762-9. doi: 10.1038/bjc.2011.145. Epub 2011 May 10.


Time dependent effects of adjuvant tamoxifen therapy on cerebrovascular disease: results from a randomised trial.

Rosell J, Nordenskjöld B, Bengtsson NO, Fornander T, Hatschek T, Lindman H, Malmström PO, Wallgren A, Stål O, Carstensen J.

Br J Cancer. 2011 Mar 15;104(6):899-902. doi: 10.1038/bjc.2011.45. Epub 2011 Feb 22.


Immunohistochemistry compared to cytosol assays for determination of estrogen receptor and prediction of the long-term effect of adjuvant tamoxifen.

Khoshnoud MR, Löfdahl B, Fohlin H, Fornander T, Stål O, Skoog L, Bergh J, Nordenskjöld B.

Breast Cancer Res Treat. 2011 Apr;126(2):421-30. doi: 10.1007/s10549-010-1202-7. Epub 2010 Oct 19.


Clinical potential of the mTOR targets S6K1 and S6K2 in breast cancer.

Pérez-Tenorio G, Karlsson E, Waltersson MA, Olsson B, Holmlund B, Nordenskjöld B, Fornander T, Skoog L, Stål O.

Breast Cancer Res Treat. 2011 Aug;128(3):713-23. doi: 10.1007/s10549-010-1058-x. Epub 2010 Oct 16.


Predictive relevance of HOXB13 protein expression for tamoxifen benefit in breast cancer.

Jerevall PL, Jansson A, Fornander T, Skoog L, Nordenskjöld B, Stål O.

Breast Cancer Res. 2010;12(4):R53. doi: 10.1186/bcr2612. Epub 2010 Jul 22.


Prolonged tamoxifen treatment increases relapse-free survival for patients with primary breast cancer expressing high levels of VEGF.

Sanchez BC, Sundqvist M, Fohlin H, Spyratos F, Nordenskjöld B, Stål O, Linderholm BK.

Eur J Cancer. 2010 Jun;46(9):1580-7. doi: 10.1016/j.ejca.2010.03.014. Epub 2010 Apr 21.


Estrogen receptor-alpha phosphorylation at serine 305, nuclear p21-activated kinase 1 expression, and response to tamoxifen in postmenopausal breast cancer.

Bostner J, Skoog L, Fornander T, Nordenskjöld B, Stål O.

Clin Cancer Res. 2010 Mar 1;16(5):1624-33. doi: 10.1158/1078-0432.CCR-09-1733. Epub 2010 Feb 23.


17ss-Hydroxysteroid dehydrogenase type 1 as predictor of tamoxifen response in premenopausal breast cancer.

Källström AC, Salme R, Rydén L, Nordenskjöld B, Jönsson PE, Stål O.

Eur J Cancer. 2010 Mar;46(5):892-900. doi: 10.1016/j.ejca.2009.12.016. Epub 2010 Jan 8.


Hypoxia, Snail and incomplete epithelial-mesenchymal transition in breast cancer.

Lundgren K, Nordenskjöld B, Landberg G.

Br J Cancer. 2009 Nov 17;101(10):1769-81. doi: 10.1038/sj.bjc.6605369. Epub 2009 Oct 20.


The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial.

de Azambuja E, McCaskill-Stevens W, Francis P, Quinaux E, Crown JP, Vicente M, Giuliani R, Nordenskjöld B, Gutiérez J, Andersson M, Vila MM, Jakesz R, Demol J, Dewar J, Santoro A, Lluch A, Olsen S, Gelber RD, Di Leo A, Piccart-Gebhart M.

Breast Cancer Res Treat. 2010 Jan;119(1):145-53. doi: 10.1007/s10549-009-0512-0.


Tamoxifen reduces the risk of contralateral breast cancer in premenopausal women: Results from a controlled randomised trial.

Alkner S, Bendahl PO, Fernö M, Nordenskjöld B, Rydén L; South Swedish and South-East Swedish Breast Cancer Groups.

Eur J Cancer. 2009 Sep;45(14):2496-502. doi: 10.1016/j.ejca.2009.05.022. Epub 2009 Jun 15.


Ratio of 17HSD1 to 17HSD2 protein expression predicts the outcome of tamoxifen treatment in postmenopausal breast cancer patients.

Jansson A, Delander L, Gunnarsson C, Fornander T, Skoog L, Nordenskjöld B, Stål O.

Clin Cancer Res. 2009 May 15;15(10):3610-6. doi: 10.1158/1078-0432.CCR-08-2599. Epub 2009 Apr 28.


Long-term effectiveness of adjuvant goserelin in premenopausal women with early breast cancer.

Hackshaw A, Baum M, Fornander T, Nordenskjold B, Nicolucci A, Monson K, Forsyth S, Reczko K, Johansson U, Fohlin H, Valentini M, Sainsbury R.

J Natl Cancer Inst. 2009 Mar 4;101(5):341-9. doi: 10.1093/jnci/djn498. Epub 2009 Feb 24.


Improved survival for women with stage I breast cancer in south-east Sweden: a comparison between two time periods before and after increased use of adjuvant systemic therapy.

Johansson P, Fohlin H, Arnesson LG, Dufmats M, Nordenskjöld K, Nordenskjöld B, Stål O; South-East Sweden Breast Cancer Study Group.

Acta Oncol. 2009;48(4):504-13. doi: 10.1080/02841860902718754.


Altered expression of cyclin E and the retinoblastoma protein influences the effect of adjuvant therapy in breast cancer.

Waltersson MA, Askmalm MS, Nordenskjöld B, Fornander T, Skoog L, Stål O.

Int J Oncol. 2009 Feb;34(2):441-8.


Gene products of chromosome 11q and their association with CCND1 gene amplification and tamoxifen resistance in premenopausal breast cancer.

Lundgren K, Holm K, Nordenskjöld B, Borg A, Landberg G.

Breast Cancer Res. 2008;10(5):R81. doi: 10.1186/bcr2150. Epub 2008 Sep 29.


Is risk of central nervous system (CNS) relapse related to adjuvant taxane treatment in node-positive breast cancer? Results of the CNS substudy in the intergroup Phase III BIG 02-98 Trial.

Pestalozzi BC, Francis P, Quinaux E, Dolci S, Azambuja E, Gelber RD, Viale G, Balil A, Andersson M, Nordenskjöld B, Gnant M, Gutierrez J, Láng I, Crown JP, Piccart-Gebhart M; BIG 02-98 Collaborative Group.

Ann Oncol. 2008 Nov;19(11):1837-41. doi: 10.1093/annonc/mdn385. Epub 2008 Jun 18.


Bisphosphonate treatment in primary breast cancer: results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer.

Kristensen B, Ejlertsen B, Mouridsen HT, Jensen MB, Andersen J, Bjerregaard B, Cold S, Edlund P, Ewertz M, Kamby C, Lindman H, Nordenskjöld B, Bergh J.

Acta Oncol. 2008;47(4):740-6. doi: 10.1080/02841860801964988.


Gene expression profiling in primary breast cancer distinguishes patients developing local recurrence after breast-conservation surgery, with or without postoperative radiotherapy.

Niméus-Malmström E, Krogh M, Malmström P, Strand C, Fredriksson I, Karlsson P, Nordenskjöld B, Stål O, Ostberg G, Peterson C, Fernö M.

Breast Cancer Res. 2008;10(2):R34. doi: 10.1186/bcr1997. Epub 2008 Apr 22.


Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.

Francis P, Crown J, Di Leo A, Buyse M, Balil A, Andersson M, Nordenskjöld B, Lang I, Jakesz R, Vorobiof D, Gutiérrez J, van Hazel G, Dolci S, Jamin S, Bendahmane B, Gelber RD, Goldhirsch A, Castiglione-Gertsch M, Piccart-Gebhart M; BIG 02-98 Collaborative Group.

J Natl Cancer Inst. 2008 Jan 16;100(2):121-33. doi: 10.1093/jnci/djm287. Epub 2008 Jan 8. Erratum in: J Natl Cancer Inst. 2008 Nov 19;100(22):1655.


In situ levels of oestrogen producing enzymes and its prognostic significance in postmenopausal breast cancer patients.

Licznerska BE, Wegman PP, Nordenskjöld B, Wingren S.

Breast Cancer Res Treat. 2008 Nov;112(1):15-23. Epub 2007 Nov 20.


HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information.

Rydén L, Landberg G, Stål O, Nordenskjöld B, Fernö M, Bendahl PO.

Breast Cancer Res Treat. 2008 May;109(2):351-7. Epub 2007 Jul 18.


PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer.

Pérez-Tenorio G, Alkhori L, Olsson B, Waltersson MA, Nordenskjöld B, Rutqvist LE, Skoog L, Stål O.

Clin Cancer Res. 2007 Jun 15;13(12):3577-84.


Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer.

Bostner J, Ahnström Waltersson M, Fornander T, Skoog L, Nordenskjöld B, Stål O.

Oncogene. 2007 Oct 25;26(49):6997-7005. Epub 2007 May 7.


Cyclin E confers a prognostic value in premenopausal breast cancer patients with tumours exhibiting an infiltrative growth pattern.

Berglund P, Stighall M, Jirström K, Rydén L, Fernö M, Nordenskjöld B, Landberg G.

J Clin Pathol. 2008 Feb;61(2):184-91. Epub 2007 May 4.


Amplification of HSD17B1 has prognostic significance in postmenopausal breast cancer.

Gunnarsson C, Jerevall PL, Hammar K, Olsson B, Nordenskjöld B, Jansson A, Stål O.

Breast Cancer Res Treat. 2008 Mar;108(1):35-41. Epub 2007 Apr 25.


Exploring the two-gene ratio in breast cancer--independent roles for HOXB13 and IL17BR in prediction of clinical outcome.

Jerevall PL, Brommesson S, Strand C, Gruvberger-Saal S, Malmström P, Nordenskjöld B, Wingren S, Söderkvist P, Fernö M, Stål O.

Breast Cancer Res Treat. 2008 Jan;107(2):225-34. Epub 2007 Apr 24.


Intact Mre11/Rad50/Nbs1 complex predicts good response to radiotherapy in early breast cancer.

Söderlund K, Stål O, Skoog L, Rutqvist LE, Nordenskjöld B, Askmalm MS.

Int J Radiat Oncol Biol Phys. 2007 May 1;68(1):50-8. Epub 2007 Mar 6.


Supplemental Content

Loading ...
Support Center